ХАЙМС Джули (US),ГИЗИНГ Деннис (US),ЛЭРРИВИЭ-ЭЛКИНС Черил (US),СИМА Майкл Дж. (US),САРМА Пурнананд (US),ГОЛДЕНХЕЙМ Пол (US)
申请号：
RU2013135170/15
公开号：
RU2013135170A
申请日:
2012.01.10
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A medicament comprising lidocaine for use in the treatment of bladder pain and / or urinary irritation symptoms by continuous administration over a treatment period of 24 hours or longer in an amount effective to achieve a therapeutic effect that persists after the treatment period. 2. The medicament according to claim 1 for use by continuously administering to the patient's bladder in an average amount of from about 10 mg to about 30 mg of lidocaine (FBE) per day. The medicament according to claim 1, wherein the duration of continuous release is from 10 to 14 days. The medicament according to claim 1, wherein the total amount of lidocaine (FBE) released continuously during the treatment period is from about 20 mg to about 400 mg. The medicament according to claim 1 for use by continuous administration, wherein the dose of lidocaine (FBE) released into the bladder is from 15 mg to 30 mg per day for the first 1-4 days of the treatment period, and then decreases to a dose of 15 mg to 3 mg per day for the remaining treatment period. 6. The medicament according to claim 5, wherein the measurable plasma concentration of lidocaine does not exceed 65 ng / ml during the maximum secretion of lidocaine in the bladder. The medicament according to claim 1 for use by continuous administration, wherein the dose of lidocaine (FBE) released into the bladder is from 25 mg to 60 mg per day for the first 1-6 days of the treatment period, and then decreases to a dose of 25 mg to 10 mg per day for the remaining treatment period. 8. The drug according to claim 7, where the measurable concentration1. Лекарственный препарат, включающий лидокаин, для применения в лечении боли в мочевом пузыре и/или симптомов раздражения при мочеиспускании путем непрерывного введения на протяжении периода лечения 24 часа или дольше в количестве, эффективном для достижения терапевтического эффекта, который сохраняется после окончания периода лечения.2. Лекарственный препарат по п.1 для применения путем неп
